The Conversation (0)
- AustraliaNorth AmericaWorld
Investing News NetworkYour trusted source for investing success
Top Stocks
Top Resource Stocks
Top Tech Stocks
Top Life Science Stocks
Trending
Trending Articles
Trending Press Releases
Trending Companies
Galan Lithium
GLN:AU
International Graphite
IG6:AU
Cardiex Limited
CDX:AU
CVD Equipment Corporation
CVV:US
Trending Reports
Resource
Popular Lists
Investing Ideas
Outlook Reports
- Lithium Outlook
- Oil and Gas Outlook
- Gold Outlook Report
- Uranium Outlook
- Rare Earths Outlook
- All Outlook Reports
Investing Guides
Tech
Popular Lists
- Top Generative AI Stocks
- Top EV Stocks
- Biggest AI Companies
- Biggest Blockchain Stocks
- Biggest Cryptocurrency-mining Stocks
- Biggest Cybersecurity Companies
- Biggest Robotics Companies
- Biggest Social Media Companies
- Biggest Technology ETFs
- Artificial Intellgience ETFs
- Robotics ETFs
- Canadian Cryptocurrency ETFs
Investing Ideas
Outlook Reports
- Artificial Intelligence Outlook
- EV Outlook
- Cleantech Outlook
- Crypto Outlook
- Tech Outlook
- All Market Outlook Reports
Investing Guides
Life Science
Popular Lists
- Cannabis Weekly Round-Up
- Top Alzheimer's Treatment Stocks
- Top Biotech Stocks
- Top Plant-based Food Stocks
- Biggest Cannabis Stocks
- Biggest Pharma Stocks
- Longevity Stocks to Watch
- Psychedelics Stocks to Watch
- Top Cobalt Stocks
- Small Biotech ETFs to Watch
- Top Life Science ETFs
- Biggest Pharmaceutical ETFs
Outlook Reports
- Life Science Outlook
- Biotech Outlook
- Cannabis Outlook
- Pharma Outlook
- Psychedelics Outlook
- All Market Outlook Reports
Investing Guides
BioSyent Releases Results for Fourth Quarter and Full Year 2017
Mar. 21, 2018 08:44AM PST
Pharmaceutical InvestingBioSyent (TSXV:RX) released today a summary of its financial results for the three and twelve months ended December 31, 2017. As quoted in the press release: “BioSyent had a strong finish to 2017 with both our Canadian and International Pharmaceutical businesses posting record quarterly sales in Q4,” commented René Goehrum, President and CEO of BioSyent. …
BioSyent (TSXV:RX) released today a summary of its financial results for the three and twelve months ended December 31, 2017.
As quoted in the press release:
“BioSyent had a strong finish to 2017 with both our Canadian and International Pharmaceutical businesses posting record quarterly sales in Q4,” commented René Goehrum, President and CEO of BioSyent. “Overall, 2017 was a year of continued organic growth, with our total sales of $20.8 million growing by 16% year-over-year. While we continued to shepherd three new products through the regulatory approval process during the year, we maintained a net profit margin of 25%. Once these new products are approved by Health Canada, they will add to the breadth and diversity of the Company’s product portfolio. We look forward to the year ahead as we continue to grow our existing brands and strive to bring new, innovative pharmaceutical and healthcare products to market.”
Outlook Reports
Featured Pharmaceutical Investing Stocks
Browse Companies
MARKETS
COMMODITIES
| Commodities | |||
|---|---|---|---|
| Gold | 2317.26 | +0.96 | |
| Silver | 27.15 | -0.03 | |
| Copper | 4.50 | +0.02 | |
| Oil | 82.96 | +0.15 | |
| Heating Oil | 2.57 | +0.01 | |
| Natural Gas | 1.64 | -0.01 | |
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.